Mirabegron
Total Payments
$6.2M
Transactions
323
Doctors
10
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $6.2M | 323 | 10 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.2M | 300 | 99.6% |
| Consulting Fee | $12,282 | 2 | 0.2% |
| Travel and Lodging | $9,065 | 14 | 0.1% |
| Food and Beverage | $394.03 | 5 | 0.0% |
| Education | $82.00 | 2 | 0.0% |
Payments by Type
Research
$6.2M
300 transactions
General
$21,823
23 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with OAB | Astellas Pharma Global Development | $3.6M | 0 |
| A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) | Astellas Pharma Global Development | $1.9M | 0 |
| Pilot feasibility study of Mirabegron to treat UUI in elderly women | Astellas Pharma Global Development | $233,333 | 0 |
| Does Mirabegron Improve Disordered Sleep in Subjects with Lower Urinary Tract Symptoms (LUTS)? | Astellas Pharma Global Development | $75,807 | 0 |
| Mirabegron Fasted Pilot Study | West-Ward Pharmaceuticals | $74,617 | 0 |
| Mirabegron and Urinary Incontinence: The Clinical Response and the Female Urinary Microbiome | Astellas US Technologies | $71,968 | 0 |
| Mirabegron Fed Pilot Study | West-Ward Pharmaceuticals | $27,345 | 0 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer | Astellas Pharma Europe BV | $24,921 | 0 |
| A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer | Astellas Pharma Global Development | $20,602 | 5 |
| A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder | Astellas Pharma Europe BV | $18,787 | 0 |
| A pilot study of the effects of Mirabegron on symptoms in patients with Interstitial Cystitis / Bladder Pain Syndrome | Astellas Pharma Global Development | $17,495 | 0 |
| A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms | Astellas Pharma Global Development | $14,244 | 3 |
| Pilot study: Mirabegron for the treatment of pain motivated urinary frequency and urgency in women, an open label study with dose escalation | Astellas Pharma Global Development | $8,709 | 0 |
| A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder | Astellas Pharma Global Development | $7,210 | 1 |
| A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder | Astellas Pharma Global Development | $3,666 | 2 |
| A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects with Overactive Bladder (OAB) | Astellas Pharma Global Development | $3,358 | 3 |
| Myrbetriq (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement | Astellas Pharma Global Development | $1,000 | 0 |
| A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder | Astellas Pharma Global Development | $522.05 | 2 |
| A Randomized, Double-Blind, Parallel Group, Placebo and Active Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder | Astellas Pharma Global Development | $522.02 | 2 |
| A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of Mirabegron in Subjects With Symptoms of Overactive Bladder | Astellas Pharma Global Development | $522.01 | 2 |
Top Doctors Receiving Payments for Mirabegron
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | — | $6.1M | 266 |
| , MD | Urology | Brighton, MA | $24,171 | 36 |
| , MD | Hypertension Specialist | Farmington, CT | $14,611 | 11 |
| , MD | Urology | Greensboro, NC | $7,940 | 1 |
| Elizabeth Mueller | Urology | Maywood, IL | $7,790 | 2 |
| , MD | Specialist | Seattle, WA | $6,465 | 1 |
| Michael Weber | — | Forest Hills, NY | $6,465 | 1 |
| , M.D | Ophthalmology | Denver, CO | $4,435 | 1 |
| , MD | Urology | Watertown, MA | $1,868 | 1 |
| , M.D | Urology | West Des Moines, IA | $441.43 | 1 |
| , MD | Obstetrics & Gynecology | Honolulu, HI | $82.00 | 2 |
Ad
Manufacturing Companies
- Astellas Pharma Global Development $6.0M
- West-Ward Pharmaceuticals $101,962
- Astellas US Technologies $71,968
- Astellas Pharma Europe BV $43,708
- Astellas Pharma US Inc $21,741
Product Information
- Type Drug
- Total Payments $6.2M
- Total Doctors 10
- Transactions 323
About Mirabegron
Mirabegron is a drug associated with $6.2M in payments to 10 healthcare providers, recorded across 323 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma Global Development.
Payment data is available from 2017 to 2017. In 2017, $6.2M was paid across 323 transactions to 10 doctors.
The most common payment nature for Mirabegron is "Unspecified" ($6.2M, 99.6% of total).
Mirabegron is associated with 20 research studies, including "A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with OAB" ($3.6M).